Hyperprogressive disease: recognizing a novel pattern to improve patient management (Q58561264)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

title

Hyperprogressive disease: recognizing a novel pattern to improve patient management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Stéphane Champiat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Christophe Massard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Benjamin Besse

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Aurélien Marabelle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Jean-Charles Soria

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Charles Ferté

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

language of work or name

English

0 references

publication date

1 December 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

30 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

page(s)

748-762

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

30 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Genomics of Immunotherapy-Associated Hyperprogressors-Letter.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

TGR analysis in phase I clinical trials--response

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Tumour growth rates and RECIST criteria in early drug development

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The effects of surgery on tumor growth: a century of investigations

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Radiation-induced reprogramming of breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Repopulation of cancer cells during therapy: an important cause of treatment failure

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

How fast is repopulation of tumor cells during the treatment gap?

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The effect of treatment duration in the local control of cervix cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Dose fractionation and tumour repopulation in radiotherapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Senescence-messaging secretome: SMS-ing cellular stress

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Targeting the tumour stroma to improve cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Progression of RAS-mutant leukemia during RAF inhibitor treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Vemurafenib-induced progression of breast cancer: a case report and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha - can tumor immune escape after immunotherapy accelerate disease progression?

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Rituximab-induced tumor progression: does it really happen?

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Hormone-induced tumor flare

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The flare phenomenon on radionuclide bone scan in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The bone scan flare phenomenon in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Healing focal "flare" phenomenon after radiotherapy in a bone metastasis from bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

De-novo and acquired resistance to immune checkpoint targeting.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Mechanisms of resistance to immune checkpoint inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Cancer immunoediting: from immunosurveillance to tumor escape

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Contrasuppression. A novel immunoregulatory activity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Induction, control, and plasticity of Treg cells: the immune regulatory network revised?

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

PD-1 marks dysfunctional regulatory T cells in malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

PD-1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The immune contexture in human tumours: impact on clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class I-alphabetaTCR interaction and become IL-10-producing active regulatory cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

T cell exhaustion during persistent viral infections

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

IDO activates regulatory T cells and blocks their conversion into Th17-like T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Neutrophils dominate the immune cell composition in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

IL-6 regulates neutrophil trafficking during acute inflammation via STAT3

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Targeting IL-17 and TH17 cells in chronic inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Cancer immunotherapy: The dark side of PD-1 receptor inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

MYC regulates the antitumor immune response through CD47 and PD-L1

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Tumorigenesis and the angiogenic switch

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

DNA damage-mediated induction of a chemoresistant niche

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

The immune contexture in cancer prognosis and treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41571-018-0111-2

7 January 2021

10.1038/S41571-018-0111-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30361681%20AND%20SRC:MED&resulttype=core&format=json